The Fly | TSHA

Taysha Gene Therapies

· TSHA

Dashboard

Financials

Ratios

Transcripts

Valuation

Yesterday

Taysha Gene Therapies 32.5M share Spot Secondary priced at $6.00

TSHA

Yesterday, 11:26 PM

Closing Bell Movers: Micron soars 14% after beat and raise

+14

Yesterday, 7:48 PM

Taysha Gene Therapies announces $200M common stock offering

TSHA

Yesterday, 4:02 PM

Tuesday

Taysha Gene Therapies price target raised by $4 at BMO Capital, here's why

TSHA

Jun 23, 9:16 AM

Taysha Gene Therapies price target raised by $1 at BofA, here's why

TSHA

Jun 23, 7:21 AM

Taysha Gene Therapies price target raised by $3 at Citizens, here's why

TSHA

Jun 23, 5:42 AM

Monday

Taysha Gene Therapies completes dosing in REVEAL pivotal trial

TSHA

Jun 22, 8:13 AM

Over a week ago

FDA Commissioner Marty Makary resigns

+17

May 12, 1:58 PM

Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)

TSHA

May 6, 8:24 AM

Unusually active option classes on open April 16th

Apr 16, 9:40 AM

Taysha Gene Therapies price target raised by $3 at Canaccord, here's why

TSHA

Apr 6, 7:00 AM

Taysha Gene Therapies reports 2025 EPS (34c), consensus (34c)

TSHA

Mar 19, 8:05 AM

Taysha Gene Therapies management to meet with Cantor

TSHA

Mar 17, 4:46 PM

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

TSHA

Mar 6, 8:07 AM

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

TSHA

Feb 6, 8:01 AM

Taysha Gene Therapies announces progress across TSHA-102

TSHA

Jan 6, 8:14 AM

Taysha Gene Therapies price target raised by $3 at Wells Fargo, here's why

TSHA

Jan 5, 7:37 AM

Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs

TSHA

Dec 4, 5:14 AM

Taysha price target raised to $19 from $13 at Cantor Fitzgerald

TSHA

Nov 21, 9:35 AM

Citizens JMP healthcare analysts hold an analyst/industry conference

Nov 18, 12:11 PM

FDA appoints Richard Pazdur as Director of CDER

+16

Nov 11, 4:27 PM

Taysha Gene Therapies price target raised by $2 at Citizens JMP, here's why

TSHA

Nov 5, 5:53 AM

Deep CNS Disease Focus: Taysha specializes in developing gene therapies for severe monogenic central nervous system (CNS) disorders, an area of high unmet medical need with limited treatment options, allowing for focused expertise and potentially accelerated regulatory pathways.

Robust AAV Gene Therapy Platform: The company leverages a sophisticated adeno-associated virus (AAV) gene therapy platform, optimized for efficient and targeted delivery of therapeutic genes to the CNS, which is critical for treating neurological conditions.

Broad and Diversified Pipeline: Taysha boasts a pipeline with multiple gene therapy candidates across various rare and severe neurological diseases, diversifying development risks and increasing the probability of bringing multiple successful treatments to market.

Clinical Trial Outcomes Uncertainty: The success of Taysha's clinical trials for its gene therapy candidates is not guaranteed, and unfavorable results or delays could significantly harm its prospects and stock value.

Regulatory Approval Hurdles: Obtaining necessary regulatory approvals for its gene therapy candidates from agencies like the FDA is a complex, lengthy, and uncertain process with no guarantee of success, which could delay or prevent market entry.

Manufacturing and Supply Chain Risks: The highly specialized and complex nature of gene therapy manufacturing presents significant challenges, including capacity limitations, quality control issues, and potential supply chain disruptions, impacting production timelines and costs.